US equities
|
NVDA
$238.84
▲+2.09%
SPCX
$168.10
▲+5.75%
MU
$1,062.42
▼-1.16%
TSLA
$380.51
▲+2.68%
MSFT
$525.92
▲+1.62%
SNDK
$1,702.96
▼-0.99%
INTC
$116.96
▼-1.99%
META
$742.51
▲+1.98%
NVDA
$238.84
▲+2.09%
SPCX
$168.10
▲+5.75%
MU
$1,062.42
▼-1.16%
TSLA
$380.51
▲+2.68%
MSFT
$525.92
▲+1.62%
SNDK
$1,702.96
▼-0.99%
INTC
$116.96
▼-1.99%
META
$742.51
▲+1.98%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by PharmaCyte Biotech, Inc.
PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment
November 25, 2025
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications
September 02, 2025
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
August 20, 2025
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors
August 18, 2025
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
May 21, 2024
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
November 15, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
FEMY
PMCB
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
October 31, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Announces Final Results of Tender Offer
June 15, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
May 11, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
February 02, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
August 15, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
July 28, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
July 21, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
July 19, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
July 11, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
July 05, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
June 15, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
June 13, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
June 02, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
May 23, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
April 27, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
April 19, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
April 13, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
April 05, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
March 22, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
March 16, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration
February 22, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
February 14, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
January 06, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
January 04, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Tickers
PMCB
